These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 6198274)

  • 1. Converting-enzyme inhibition corrects the altered adrenal response to angiotensin II in essential hypertension.
    Taylor T; Moore TJ; Hollenberg NK; Williams GH
    Hypertension; 1984; 6(1):92-9. PubMed ID: 6198274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives.
    Redgrave J; Rabinowe S; Hollenberg NK; Williams GH
    J Clin Invest; 1985 Apr; 75(4):1285-90. PubMed ID: 2985655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension.
    Shoback DM; Williams GH; Moore TJ; Dluhy RG; Podolsky S; Hollenberg NK
    J Clin Invest; 1983 Dec; 72(6):2115-24. PubMed ID: 6358261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged converting enzyme inhibition in non-modulating hypertension.
    Dluhy RG; Smith K; Taylor T; Hollenberg NK; Williams GH
    Hypertension; 1989 Apr; 13(4):371-7. PubMed ID: 2538393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The adrenal receptor for angiotensin II is altered in essential hypertension.
    Williams GH; Hollenberg NK; Moore TJ; Swartz SL; Dluhy RG
    J Clin Invest; 1979 Mar; 63(3):419-27. PubMed ID: 219037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous angiotensin II as a determinant of sodium-modulated changes in tissue responsiveness to angiotensin II in normal man.
    Shoback DM; Williams GH; Hollenberg NK; Davies RO; Moore TJ; Dluhy RG
    J Clin Endocrinol Metab; 1983 Oct; 57(4):764-70. PubMed ID: 6309884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Captopril enhances vascular and adrenal responsiveness to angiotensin II in essential hypertension.
    Koletsky RJ; Gordon MB; LeBoff MS; Moore TJ; Dluhy RG; Hollenberg NK; Williams GH
    Clin Sci (Lond); 1984 Mar; 66(3):299-305. PubMed ID: 6362960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volume control and altered renal and adrenal responsiveness to angiotensin in essential hypertension: implications for treatment with converting enzyme inhibition.
    Hollenberg NK; Williams GH
    J Hypertens Suppl; 1983 Oct; 1(1):119-28. PubMed ID: 6100600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Converting enzyme inhibitors normalize the reduced adrenal responsiveness to angiotensin II in essential hypertension.
    Williams GH; Hollenberg NK
    J Hypertens Suppl; 1984 Dec; 2(2):S43-7. PubMed ID: 6100876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma aldosterone response to angiotensin II in sodium-restricted elderly subjects with essential hypertension.
    Morimoto S; Uchida K; Miyamoto M; Kigoshi T; Morise T; Takimoto H; Takeda R
    J Am Geriatr Soc; 1981 Jul; 29(7):302-7. PubMed ID: 7016959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal renin short feedback loop in essential hypertension is reversible with converting enzyme inhibition.
    LeBoff Ms; Dluhy RG; Hollenberg NK; Moore TJ; Koletsky RJ; Williams GH
    J Clin Invest; 1982 Aug; 70(2):335-41. PubMed ID: 6284799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin-converting enzyme inhibition: direct and indirect mechanisms].
    Stumpe KO
    Klin Wochenschr; 1985 Sep; 63(18):897-906. PubMed ID: 2997540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal and adrenal responsiveness to angiotensin II: influence of beta adrenergic blockade.
    Gordon MS; Williams GH; Hollenberg NK
    Endocr Res; 1992; 18(2):115-31. PubMed ID: 1516563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal adrenal responsiveness and angiotensin II dependency in high renin essential hypertension.
    Dluhy RG; Bavli SZ; Leung FK; Solomon HS; Moore TJ; Hollenberg NK; Williams GH
    J Clin Invest; 1979 Nov; 64(5):1270-6. PubMed ID: 500810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are non-modulating patients with essential hypertension a distinct subgroup? Implications for therapy.
    Williams GH; Hollenberg NK
    Am J Med; 1985 Sep; 79(3C):3-9. PubMed ID: 2996343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of subpressor doses of angiotensin II on renal hemodynamics in relation to blood pressure.
    Ljungman S; Aurell M; Hartford M; Wikstrand J; Berglund G
    Hypertension; 1983; 5(3):368-74. PubMed ID: 6341220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-mediated modulation of aldosterone secretion: impact of converting enzyme inhibition on rat glomerulosa cell response to angiotensin-II.
    Braley LM; Menachery A; Rystedt L; Williams GH
    Endocrinology; 1989 Sep; 125(3):1310-4. PubMed ID: 2547581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced aldosterone response to angiotensin II in human hypertension.
    Kisch ES; Dluhy RG; Williams GH
    Circ Res; 1976 Jun; 38(6):502-5. PubMed ID: 178461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone regulation in essential hypertension: altered adrenal responsiveness to angiotensin II.
    Williams GH; Dluhy RG; Moore TJ
    Mayo Clin Proc; 1977 May; 52(5):312-6. PubMed ID: 870773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin system in two genetically normotensive strains of Lyon rats.
    Lantelme P; Lo M; Sassard J
    Am J Hypertens; 2000 Mar; 13(3):283-9. PubMed ID: 10777033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.